loading page

Anticoagulant in Patients with Pulmonary Embolism and Fatty Liver: A Case Report
  • +7
  • Sha-Sha Li,
  • Wei-Xian Lin,
  • Kun-Yu Huang,
  • Sheng-Yang Chen,
  • Juan Chen,
  • Yu-Ping Wang,
  • Lian-Fang Xue,
  • Hui Liu,
  • Jing-Hao Wang,
  • Qing Zhang
Sha-Sha Li
Jinan University First Affiliated Hospital
Author Profile
Wei-Xian Lin
Southern Medical University Nanfang Hospital
Author Profile
Kun-Yu Huang
Jinan University First Affiliated Hospital
Author Profile
Sheng-Yang Chen
The Third Affiliated Hospital (The Affiliated Luohu Hospital) of Shenzhen University
Author Profile
Yu-Ping Wang
Jinan University First Affiliated Hospital
Author Profile
Lian-Fang Xue
Jinan University First Affiliated Hospital
Author Profile
Hui Liu
Jinan University First Affiliated Hospital
Author Profile
Jing-Hao Wang
Jinan University First Affiliated Hospital
Author Profile
Qing Zhang
Southern Medical University Nanfang Hospital
Author Profile

Peer review status:UNDER REVIEW

01 Jun 2020Submitted to British Journal of Clinical Pharmacology
17 Jun 2020Assigned to Editor
17 Jun 2020Submission Checks Completed
21 Jun 2020Reviewer(s) Assigned

Abstract

Abstract: Patients with liver disease are more prone to thrombosis and bleeding events than healthy people. The decision to use anticoagulation in patients with pulmonary embolism and liver disease requires a cautious evaluation of the risks of bleeding and the benefits of anticoagulation. In this paper, we reported a case of a patient with fatty liver that developed pulmonary embolism. Although the low molecular weight heparin sodium injection was only administered at a regular dose, the patient still developed epistaxis and hematuria. After evaluating the efficacy and safety of different anticoagulants in patients with pulmonary embolism and liver dysfunction, rivaroxaban is more suitable for this patient to be treated by sequential therapy. After three weeks of treatment with rivaroxaban, the patient’s blood routine test results were normal, and no side effect was found. As far as we know, this is the first reported anticoagulant therapy case for patients with pulmonary embolism and fatty liver.